Pharmaceuticals, Biotechnology and Life Sciences
IRVINE, Calif.–(BUSINESS WIRE)–$NVUS–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of…
Sales & Marketing Expense as a Percentage of Total Revenue Declined to 41.7% for the three months ended June 30,…
Milestone Pharmaceuticals gets to advance its pivotal program of etripamil, its novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT), the company said in an quarter and half year financial update.
Eli Lilly’s Taltz met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, testing Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications.
Initiated a Non-IND, IRB-Approved Clinical Study for AXA1957 in adolescent subjects with NAFLD Announced the publication in Frontiers of data…
Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable clinical benefit with…
HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter…
Another successful outcome from a Versant-created company in a breakthrough field SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia…
Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Expected to be Completed in Fourth Quarter 2019…